UNIGE document Professional Article
previous document  unige:33658  next document
add to browser collection

Ostéoporose chez l'homme

Published in Revue médicale suisse. 2013, vol. 9, no. 390, p. 1260-4
Abstract One man out of 5 experiences an osteoporotic fracture in his remaining lifetime at 50 years. Many comorbidities are associated with osteoporosis and fracture risk in men, with numerous associated risk factors beyond a decrease in bone mineral density (BMD), and also taking into account the risk of falling. A prevalent fragility fracture, oral glucocorticoid therapy for at least 3 months, and androgen deprivation therapy for prostate cancer are the three most common situations of increased risk of osteoporosis in men. Bisphosphonates, denosumab and teriparatide increase BMD and change bone turnover markers in the same magnitude as in women. The first anti-fracture data in men were obtained with zoledronic acid and denosumab.
Keywords Accidental FallsAndrogen Antagonists/adverse effects/therapeutic useBone DensityBone Density Conservation Agents/therapeutic useFemaleGlucocorticoids/administration & dosage/adverse effectsHumansMaleOsteoporosis/drug therapy/epidemiology/etiologyOsteoporotic Fractures/epidemiologyProstatic Neoplasms/drug therapyRisk FactorsSex Factors
PMID: 23821844
Full text
Article (Published version) (764 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://rms.medhyg.ch/numero-390-page-1260.htm
Research group Nutrition et os (66)
(ISO format)
BIVER, Emmanuel, UEBELHART, Brigitte Florence. Ostéoporose chez l'homme. In: Revue médicale suisse, 2013, vol. 9, n° 390, p. 1260-4. https://archive-ouverte.unige.ch/unige:33658

491 hits

0 download


Deposited on : 2014-01-24

Export document
Format :
Citation style :